Trial Profile
Multicentre, Randomized, Placebo-controlled, Double-blind, Phase I/IIa Dose-escalation Clinical Study of a Therapeutic Vaccine (VAC-3S) Intended to Confer Protection Against Immunopathological Effects of HIV-1 in Infected Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs VAC 3S (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Biomarker
- Sponsors InnaVirVax
- 01 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 18 Dec 2013 Planned end date changed from 1 Dec 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.
- 06 Mar 2013 Interim tolerability analysis as well as full data for immunogenicity endpoints presented at the 20th Conference on Retroviruses and Opportunistic Infections.